Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017
27 Mars 2017 - 1:00PM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and Clostridium difficile infection, will be
announcing its financial results for the fourth quarter and fiscal
year ended 31 January 2017 on Wednesday, 29 March 2017.
Summit will host a conference call the same day
at 1:00pm BST / 8:00am EDT. Conference call information will be
included in the full year results press release and a replay of the
call will also be available through the Company's website,
www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit
Therapeutics |
|
|
|
Glyn Edwards
/ Richard Pye (UK office)Erik Ostrowski / Michelle
Avery (US office) |
|
Tel: |
+44 (0)1235 443 951+1 617
225 4455 |
Cairn Financial
Advisers LLP |
|
|
|
(Nominated Adviser)Liam
Murray / Tony Rawlinson |
|
Tel: |
+44 (0)20 7213 0880 |
N+1
Singer |
|
|
|
(Broker)Aubrey Powell /
Jen Boorer |
|
Tel: |
+44 (0)20 7496 3000 |
MacDougall
Biomedical Communications |
|
|
|
(US media contact) |
|
Tel: |
+1 781 235 3060 |
Chris Erdman / Karen
Sharma |
|
cerdman@macbiocom.com ksharma@macbiocom.com |
Consilium
Strategic Communications |
|
|
|
(Financial public
relations, UK) |
|
Tel: |
+44 (0)20 3709 5700 |
Mary-Jane Elliott / Sue
Stuart / Jessica Hodgson / Lindsey Neville |
|
summit@consilium-comms.com |
-END-
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024